Contents

Search

oteseconazole

Indications: - recurrent vulvovaginal candidiasis * for use in women not of reproductive potential Dosage: - 600 mg oteseconazole on day 1, 450 mg oteseconazole on day 2 Mechanism of action: - oteseconazole inhibits CYP51, an fungal enzyme that preserves integrity of their cell walls

General

pyrrole antifungal agent

References

  1. Marcus A FDA Approves Oteseconazole for Chronic Yeast Infections. Medscape. April 28, 2022 https://www.medscape.com/viewarticle/972882